This data is for laboratory research purposes only. Not for human or animal consumption.
What is GHRP-6?
GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide growth hormone secretagogue (GHS) that binds to the ghrelin receptor (GHSR-1a) to stimulate pulsatile GH release and exert pleiotropic cytoprotective effects across cardiac, hepatic, and neural tissues. With a molecular formula of C₄₆H₅₆N₁₂O₆ and a molecular weight of approximately 873 g/mol, GHRP-6 shares structural and pharmacological similarities with GHRP-2 but has accumulated a distinct body of research focused on cardioprotection, anti-inflammatory signaling, and tissue repair — beyond its originally characterized role as a GH secretagogue. It is not FDA-approved for any therapeutic indication and is studied exclusively in preclinical and investigational contexts.
Mechanism of Action
GHRP-6 activates the GHSR-1a receptor, a Gαq/11-coupled G protein-coupled receptor expressed in anterior pituitary somatotroph cells, hypothalamic nuclei, cardiac myocytes, and hepatocytes. Receptor activation initiates phospholipase C–mediated IP₃/DAG signaling, triggering intracellular calcium mobilization and downstream kinase cascades that promote GH granule exocytosis from pituitary somatotrophs.
Beyond GH axis stimulation, GHRP-6 demonstrates GHSR-1a-mediated cytoprotection through several converging pathways:
- Mitochondrial metabolic reprogramming: Upregulation of fatty acid β-oxidation enzymes, enabling post-ischemic cardiac tissue to shift energy metabolism toward lipid substrates and preserve ATP production under hypoxic conditions
- Anti-apoptotic signaling: Induction of BCL-2 family anti-apoptotic proteins, reducing cardiomyocyte death following ischemia-reperfusion or permanent ligation injury
- Antioxidant defense: Upregulation of superoxide dismutase (SOD), catalase, and peroxiredoxins — reducing reactive oxygen species (ROS) burden in post-infarct myocardium
- Mitochondrial respiratory chain preservation: Proteomic analysis reveals concurrent upregulation of electron transport chain complexes, supporting oxidative phosphorylation under metabolic stress
Unlike GHRP-2, GHRP-6 stimulates appetite and food intake through hypothalamic GHSR-1a activation of NPY/AgRP circuits — a property noted in rodent feeding studies and mechanistically related to the GHSR system's broader role in energy homeostasis.
Cardioprotective Research (Anchor Study — PMID 41901314)
The 2026 study by Díaz-Regueira et al. examined GHRP-6 in a non-reperfusion myocardial infarction model via permanent LAD coronary artery ligation in Sprague-Dawley rats. Key findings:
- Minimum effective dose: 0.4 mg/kg established as the threshold for measurable inotropic enhancement on echocardiographic parameters in healthy rats
- Left ventricular preservation: GHRP-6 treatment (initiated immediately post-surgery, continued 7 days) attenuated LV wall thinning and ventricular ballooning compared to saline controls
- Fibrosis reduction: Histological analysis demonstrated significantly reduced myocardial interstitial fibrosis and scar tissue formation in GHRP-6-treated infarct animals versus saline-treated infarct controls
- Functional improvement: Integrated improvements in ejection fraction and fractional shortening on echocardiographic evaluation at day 7 post-infarction
- Mitochondrial proteomics (6-hour timepoint): Concurrently upregulated proteins spanning fatty acid β-oxidation, apoptosis prevention, antioxidant defense, and mitochondrial respiratory complex subunits — suggesting rapid mitochondrial reprogramming as the mechanistic substrate for the observed cardioprotection
Broader Preclinical Research Profile
GHRP-6's research literature extends beyond cardioprotection:
- Hepatoprotection: Published rodent models have documented GHRP-6 attenuation of liver fibrosis and steatohepatitis, with mechanistic data implicating TGF-β1 pathway modulation and stellate cell quiescence — independent of its GH-stimulating effects
- Wound healing and tissue repair: Anti-inflammatory cytokine modulation (TNF-α suppression, IL-6 reduction) has been observed in wound models, mechanistically overlapping with GHRP-6's cytoprotective signaling
- Neuroprotection: Preclinical stroke and excitotoxicity models have reported GHRP-6 attenuation of neuronal apoptosis through GHSR-1a-mediated PI3K/Akt activation
- GH axis and IGF-1: As a GHS, GHRP-6 stimulates not only acute GH pulses but, with sustained administration in rodent studies, increases circulating IGF-1 — a downstream mediator of many GH-dependent anabolic effects
Comparison to Related GHRPs
GHRP-6 is distinguished from related secretagogues by several properties relevant to research design:
- vs GHRP-2: GHRP-2 produces modestly higher peak GH responses per unit dose in direct comparisons; GHRP-6 is more extensively studied for cardioprotective and hepatoprotective applications
- vs Ipamorelin: Ipamorelin is a pentapeptide with superior receptor selectivity (negligible cortisol/prolactin elevation); GHRP-6 stimulates appetite and has a wider published cytoprotective literature
- vs Hexarelin: Hexarelin (examorelin) is structurally related and shares some cardioprotective properties; GHRP-6 has the more extensive cardiac research literature of the two
Regulatory Status
GHRP-6 is not FDA-approved for any indication. It is not classified as a controlled substance. Its availability through 503A compounding pharmacies places it within the same regulatory landscape as other investigational peptides currently under PCAC review. GHRP-6 is listed on the WADA Prohibited List under category S2 (peptide hormones, growth factors, and related substances), making it prohibited year-round for athletes subject to anti-doping testing.